# US 2026/0062457 A1 · Extracellular domain of alpha subunit of ige fc receptor, pharmaceutical composition comprising same and method for producing same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062457 A1
- Document ID: US20260062457A1
- Status: Published application
- Kind: A1
- Application number: 19/294,680
- Filed: 2025-08-08
- Published: 2026-03-05
- Earliest claimed: 2018-01-08
- Assignees: Gi Innovation, Inc.
- Applicants: GI Innovation, Inc.
- Inventors: Young Chul Sung; Zungyoon Yang; Myung Ho Jang
- Web page: https://patentgrep.com/patent/US20260062457A1

## CPC

- C07K 14/70535: {Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)}
- A23L 33/18: Peptides; Protein hydrolysates
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C12N 15/62: DNA sequences coding for fusion proteins
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed is a polypeptide dimeric protein containing two monomers, each of which contains an extracellular domain (FcεRIa-ECD) of an alpha subunit of an IgE Fc receptor. The dimeric protein has advantages that an excellent binding ability to IgE is exhibited as compared with a conventional therapeutic agent containing an anti-IgE antibody, and less other side effects are exhibited due to lack of ADCC and CDC functions. Thus, the dimeric protein can be applied to a medical product for treating or preventing an IgE-mediated allergic disease.

## Claims

### Claim 1

A method for treating or preventing an allergic disease, comprising a step of administering to a subject the polypeptide dimer, which comprising:
two monomers, each of which comprises an extracellular domain of an alpha subunit of an IgE Fc receptor (FcεRIa-ECD), a modified Fc region, and a hinge,
wherein the modified Fc region and the FcεRIa-ECD are linked via the hinge.

### Claim 2 (depends on 1)

The method of claim 1,
wherein the extracellular domain of the alpha subunit of the IgE Fc receptor is the amino acid sequence of SEQ ID NO: 1 or a fragment thereof.

### Claim 3 (depends on 1)

The method of claim 1,
wherein the modified Fc region is SEQ ID NO: 2.

### Claim 4 (depends on 1)

The method of claim 1,
wherein the hinge is a hinge region derived from an immunoglobulin IgD or a variant thereof.

### Claim 5 (depends on 4)

The method of claim 4,
wherein the hinge region derived from an immunoglobulin IgD or the variant thereof contains at least one cysteine.

### Claim 6 (depends on 4)

The method of claim 4,
wherein the hinge region derived from an immunoglobulin IgD or the variant thereof is Arg Asn Thr Gly Arg Gly Gly Glu Glu Lys Lys Xaa1 Xaa2 Lys Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr Pro Glu Cys Pro (SEQ ID NO: 17),
Xaa1 is Lys or Gly, and
Xaa2 is Glu, Gly, or Ser.

### Claim 7 (depends on 4)

The method of claim 4,
wherein the hinge region derived from an immunoglobulin IgD or the variant thereof is Ala Gln Pro Gln Ala Glu Gly Ser Leu Ala Lys Ala Thr Thr Ala Pro Ala Thr Thr Arg Asn Thr Gly Arg Gly Gly Glu Glu Lys Lys Xaa3 Xaa4 Lys Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr Pro Glu Cys Pro (SEQ ID NO: 18),
Xaa3 is Lys or Gly, and
Xaa4 is Glu, Gly, or Ser.

### Claim 8 (depends on 1)

The method of claim 1,
wherein the hinge has any one amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 19.

### Claim 9 (depends on 1)

The method of claim 1,
wherein the allergic disease is any one selected from the group consisting of atopic dermatitis, asthma, allergic rhinitis, allergic conjunctivitis, allergic dermatitis, chronic idiopathic urticaria, and allergic contact dermatitis.
